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Management
Emily Zhang and Trine N. Jorgensen
Abstract
In this chapter, we will describe neuropsychiatric lupus (NPSLE) as it develops 
and is treated in lupus patients, as well as means to study the disease using animal 
models. Based on mouse studies, we will discuss the correlation between inflam-
matory mediators, such as cytokines and autoantibodies, and the development 
of neurological symptoms with specific emphasis on the evidence for systemic 
versus local effects. We will describe specifically the effect of these mediators on 
the blood-brain barrier, microglia cell function, and the immune system. In addi-
tion, we will summarize signs and symptoms in NPSLE patients, especially with 
respect to primary versus drug-induced neurological issues and current treatment 
strategies. The chapter will offer a comprehensive review of old and new studies in 
animal models and patient populations and offer insight into how these results align 
with current treatment strategies offered to patients.
Keywords: neuropsychiatric lupus, animal models, autoantibodies, cytokines, 
treatment
1. Introduction
This chapter covers aspects of neuropsychiatric systemic lupus erythematosus 
(NPSLE), including basic science, as well as clinical features and management. 
Animal studies have been invaluable in informing our knowledge of pathogenesis 
and pathophysiology, especially in regard to elucidating immune mechanisms. 
Studies in two of the most commonly used mouse models, MRL/lpr and (NZB/
NZW)F1 (NZB/W), have led to the identification of autoantibodies and cytokines 
implicated in NPSLE development. Specific antibodies include anti-NMDA-NR2 
and anti-ribosomal P antibodies, as well as anti-phospholipid antibodies, that may 
play a role in perturbing the blood-brain barrier (BBB). There is evidence that BBB 
permeability may be the second hit needed to induce NPSLE, and cytokines have 
been repeatedly implicated in this process. Clinical correlations strengthen the 
argument for autoantibody and cytokine involvement in the pathogenesis, given the 
discovery of elevated cytokine and autoantibody titers in cerebrospinal fluid (CSF) 
from patients. Additionally, studies have been performed, whereby autoantibodies 
identified in NPSLE patients were injected into mouse models to induce an NPSLE 
phenotype.
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Since microglia are the major immune cells of the brain, we separately discuss 
how their activation can lead to pathophysiology. A connection with estrogen recep-
tors may also exist as seen in MRL/lpr mice. In addition, new evidence suggests that 
one of the most frequently studied cytokines in SLE, interferon-α (IFNα), may play 
an important role in NPSLE etiology. As such, studies have shown that deficiency in 
the IFNα/β receptor can reduce both systemic and neurological diseases in multiple 
lupus mouse models. Interestingly, IFNα has been independently associated with 
mood and cognitive symptoms, as seen in the side effects experienced by those who 
use it as treatment for various cancers and viral infections.
One aspect of NPSLE research that delves more into the clinical realm is the 
identification of biomarkers. A number of studies have looked at various potential 
biomarkers, including the aforementioned cytokines and autoantibodies. We review 
the evidence and emphasize the lack of consistent correlation, which is often a result 
of the wide ranging, vague, and often subjective manifestations of NPSLE. These 
include cerebrovascular disease, seizures, myelopathy, aseptic meningitis, move-
ment disorders, and demyelinating syndrome. Psychiatric features have also been 
described, such as psychosis and mood changes. Some of the more vague symptoms 
include cognitive dysfunction and acute confusional state. Because these clinical 
features often overlap with other neuropsychiatric conditions and many of these 
symptoms are difficult to quantify, reports of epidemiology are highly variable 
ranging anywhere from a prevalence as low as 12% to as high as 95%. Although 
NPSLE still often remains a diagnosis of exclusion, we cover consensus case- 
definition criteria and explore the role, if any, of imaging such as quantitative MRI.
Lastly, we discuss the management of NPSLE, which, due to the complex-
ity in diagnosis and lack of disease activity markers, has been mostly empirical. 
Corticosteroids and immunomodulators continue to be the mainstays of treatment, 
although they present numerous side effects. In addition, symptomatic therapy, 
including anticonvulsants, antidepressants, or antipsychotic medications, can be 
used. Antiplatelet and anticoagulation therapy should also be considered to manage 
cerebrovascular risk factors in those with antiphospholipid antibodies. In summary, 
the body of knowledge about the pathophysiology of NPSLE leaves much to be 
desired. Further studies in mouse models are necessary to identify more consistent 
biomarkers and develop targeted treatments for patients suffering from this disease.
2. Animal models used to study neurolupus
Given the difficulties in studying NPSLE in patients due to unclear associations 
with symptoms and timing of diagnosis, as well as overlap with other neurological 
and psychiatric syndromes, the use of murine models has been invaluable for eluci-
dation of pathological mechanisms and identification of better therapeutic targets. 
Three families of murine models for SLE have been studied, including spontaneous 
models, induced models, and genetically engineered models. Within spontane-
ous models, typically generated by selective inbreeding, the most commonly used 
models to study neuropsychiatric manifestations include the F1 hybrid between 
New Zealand Black (NZB) and New Zealand White (NZW) mice called the (NZB/
NZW)F1 hybrid (NZB/W) and the Murphy Roths large (MRL) strain [1]. NPSLE 
has not been studied extensively in induced or genetically engineered models.
2.1 MRL/lpr mice
The MRL/lpr model carries a spontaneously occurring mutation in the lympho-
proliferative (lpr) gene on the MRL inbred background. The lpr mutation is linked to 
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a variation in the fas gene that causes failure of lymphocytes to undergo apoptosis [2]. 
The result of this mutation is the accumulation of CD4, CD8, and CD3 T cells in lym-
phoid tissue [3]. MRL/lpr mice develop an accelerated and aggressive lupus-like disease 
characterized by immune-mediated damage to the kidneys, skin, heart, lungs, joints, 
and brain and by the presence of circulating autoantibodies against dsDNA and Smith 
antigen [1]. Young MRL/lpr mice also spontaneously develop behavioral dysfunction 
and mood changes, as well as a depressive-like behavior as measured by the forced-
swim test [4]. The presence of depressive symptoms in MRL/lpr mice has been found 
to correlate with titers of autoantibodies against dsDNA, the NMDA receptor, and 
cardiolipin [4]. Additionally, MRL/lpr mice display loss of preference for sweetened 
fluids, reflecting anhedonia, which is a core feature of major depression in humans [5].
Brain growth appears to be stunted in MRL/lpr mice, and ventricles increase in 
size along with development of autoimmune manifestations [1, 6]. More specifi-
cally, increased neurodegeneration, reduced dendritic complexity, and progressive 
atrophy of pyramidal neurons have been seen in the hippocampi of MRL/lpr mice 
[1]. Cyclophosphamide immunosuppression prevented atrophy and increased 
dendritic branching in MRL/lpr, thereby supporting the notion that autoimmunity 
is at least partly responsible for decreased brain growth possibly also affecting 
behavioral alterations [7].
Finally, SLE in humans has a well-known sex bias affecting females 9–10 times more 
than males [8]. Interestingly, this bias seems to be recapitulated in the depressive phe-
notype and autoantibody titers of MRL/lpr mice, with females exhibiting accelerated 
signs of both depression and autoantibodies as early as 5 weeks as compared to 18 weeks 
in males [9]. This suggests that autoantibodies may be implicated in the pathogenesis of 
NPSLE phenotype in this mouse model, as will be discussed further below.
2.2 (NZB/NZW)F1 mice
The NZB/W model develops a spontaneous and severe autoimmune disease 
with autoantibodies and defective immune complex clearance [10]. Manifestations 
of lupus in the NZB/W model resemble those of MRL/lpr mice. While they do not 
develop lymph node hyperplasia, they succumb to a progressive glomerulonephritis 
leading to fatal renal failure [2]. The sex bias of SLE is also recapitulated in NZB/W 
mice, with female mice exhibiting accelerated disease [11]. Beneficial effects from 
treatment with antiestrogen agent tamoxifen suggest that the sex difference is at least 
partly due to estrogen [12]. Signs of neurolupus in NZB/W mice manifest as progres-
sively increasing anxiety behavior and decreasing exploratory behavior [13], as well as 
learning and memory deficits that develop later in the disease course [14]. Moreover, 
immunosuppressive treatment with cyclophosphamide and prednisolone alleviated 
behavioral deficits in this mouse model [15]. Brains of NZB/W mice have mononu-
clear infiltration of cerebral and hippocampal blood vessels and in the choroid plexus 
[14]. Moreover, the mice display a reduction in neuropeptides, namely neuropeptide 
Y, substance P, and calcitonin gene-related peptide P in the cortex, hippocampus, and 
hypothalamus that correlate with the development of neurological deficits [16]. It 
was in this mouse model that anti-dsDNA antibodies were found to be cross-reactive 
with a peptide sequence, which was also found in humans and later identified to be a 
subunit of a neurotransmitter receptor (NMDAR-NR2) [17, 18], as addressed below.
3. Understanding of NPSLE-like pathogenesis
Polyclonal B cell activation and autoantibody production seem to play a major 
role in the pathogenesis of SLE; however, the initial events leading to this activation 
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and deregulation remain undetermined [2]. Still, overwhelming evidence supports 
a pathogenic role for autoantibodies as will be discussed further below.
One consideration necessary when discussing NPSLE pathogenesis, however, is how 
antibodies produced subsequent to B cell activation gain access to the CNS. The brain is 
immunoprivileged due to the existence of multiple barriers regulating entry of immune 
cells and compounds such as antibodies. As a result, it has long been thought that some 
kinds of disruption in these barriers are necessary for NPSLE disease to manifest [19]. 
This notion is further supported by the observation that some SLE patients have brain 
reactive autoantibodies in their sera but do not have neuropsychiatric disease [20, 21].
3.1 Three types of barriers
In addition to a high metabolic demand, the brain requires a tightly regulated 
environment free of toxins and pathogens, which is maintained by three types of 
barriers: the blood-brain barrier (BBB), the meningeal barrier in the arachnoid 
matter, and the blood-cerebrospinal-fluid-barrier (BCSFB) [19]. Due to the paucity 
of data in the literature, the meningeal barrier will not be further discussed here.
The BBB is perhaps the most widely discussed of the three, as it protects the brain 
from toxic elements in the blood but also allows for the entry and exit of compounds in 
a finely controlled manner [19]. This balance is achieved via coordination between mul-
tiple cell types that are collectively known as the neurovascular unit (NVU) [22–24].  
The NVU consists of endothelial cells lining the capillaries, neurons, astrocytes, 
pericytes, and microglia [22]. Tight junctions between endothelial cells form a layer on 
the luminal side of capillaries, thereby restricting paracellular diffusion. Pericytes are 
embedded in the basal lamina matrix that surrounds endothelial cells, and astrocyte 
endfeet reside on the outer surface of the basal lamina [22]. Astrocytes are thus able to 
communicate with both vasculature, as well as local neurons. Finally, resident microg-
lia use long processes to survey the microenvironment near the NVU [22].
The BCSFB separates the blood from the ventricular system, which is comprised 
of the lateral, CSF-filled third and fourth ventricles. CSF is produced and secreted 
by the choroid plexus, which consists of cuboidal epithelium that, among other 
characteristics, contains transporters that regulate CSF composition [25]. Albumin 
quotient and IgG index in the CSF are commonly used surrogates for BBB disrup-
tion; however, it should be noted that it is difficult to distinguish whether the source 
of these molecules is from BBB or BCSFB disruption, and further studies are needed 
to determine the relative importance of these barriers [19].
Historically, studies in mice have suggested that there need to be a “second hit,” 
namely a breach in the BBB for antibodies to access the brain, however, was recently 
challenged by studies failing to find an effect of BBB disruption [26], but rather 
an impact of BCSFB disruption [27]. As such, using exogenous tracers, Gelb et al. 
failed to find significant changes in BBB permeability in MRL/lpr mice but found 
abnormal function of the BCSFB in the choroid plexus, a potential site for lympho-
cyte infiltration [27]. Further studies are needed to identify the relative significance 
of BBB and/or BCSFB disruption in different animal models and in response to 
different inflammatory factors including cytokines and autoantibodies.
3.2 Evidence for BBB permeability
Older MRL/lpr mice have significant elevations of IgG and albumin levels in 
the CSF, suggestive of BBB disruption [28]. This is further corroborated by studies 
showing IgG filtration into brain parenchyma in MRL/lpr mice and increased per-
meability of nonautoimmune endothelial cells on treatment with serum from MRL/
lpr mice compared with serum from controls [29]. Interestingly, these effects were 
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found to be mediated by terminal complement factor C5a [29], although further 
studies investigating the influence of complement on neurolupus phenotypes in 
MRL/lpr mice have yet to be performed. Another possible sign of BBB disruption 
is the finding that CD3 T cells penetrate into the choroid plexus and parenchyma 
of MRL/lpr mice [30]. Interestingly, the presence of brain infiltrating CD3 T cells 
was accompanied by splenomegaly and retarded brain growth [30], suggesting 
leukocyte infiltration as a mechanism for neurodegeneration. Finally, the BBB of 
MRL/lpr mice has also been found to stain for C1q complement particles and IgG, 
suggesting the presence of immune complexes [31], although whether such com-
plexes are functional or diagnostic remains to be determined. Finally, it should be 
mentioned that aquaporin 4 expression was increased in brains of MRL/lpr mice 
but reduced in response to a soluble complement inhibitor, suggesting that comple-
ment may play a specific role in driving cerebral edema and inflammation [31].
3.3 Brain-reactive antibodies
Evidence for the presence and involvement of brain-reactive antibodies (BRA) 
comes from the finding that levels of CSF IgG correlate with immobility on the forced-
swim test in MRL/lpr mice [32]. Specific BRAs have been identified and suggested to 
play a role in initiating, driving, or propagating NPSLE and will be discussed below.
3.3.1 Anti-NR2 antibodies
Glutamate is the main excitatory neurotransmitter of the brain, and the 
N-methyl-D-aspartate receptor (NMDAR) is an ionotropic glutamate receptor 
subtype consisting of two NR1 subunits in a complex with two of the four NR2 (a–d) 
or two NR3 (a and b) subunits [33]. It was discovered in the early 2000s that a subset 
of anti-dsDNA antibodies cross-react with the NR2 subunit of the NMDA receptor 
[34]. Anti-NR2 antibodies have been found in the sera of both NZB/W and MRL/
lpr mice and correlate with hippocampal and amygdala neuronal dysfunction and 
death even before NPSLE symptoms [17, 18, 35]. Neurons in the amygdala, anterior 
hypothalamus, cerebellum, and the hippocampus express a high density of NMDARs 
with subunits NR2a and NR2b [36], and so it follows that anti-NR2 antibodies would 
correspond with cognitive dysfunction. In clinical studies of SLE patients, up to 81% 
carry the anti-NMDA-NR2 antibodies, and anti-NR2 titers in the CSF of SLE patients 
correlate with diffuse symptoms, such as cognitive impairment, memory decline, 
impaired attention or executive functions, and depression [37]. The pathogenicity of 
anti-NR2 antibodies was further corroborated by the finding that transfer of isolated 
antibodies from lupus patient serum directly into the brains of nonautoimmune 
mice-induced neuronal cell death and impaired cognition [38, 39]. Interestingly, 
the concentration of anti-NR2 autoantibodies affects the function of the NMDA 
receptor differently; while low concentrations change synaptic function, high 
concentrations promote excitotoxicity, resulting in neuronal cell death by overacti-
vation of glutamate receptors and excessive calcium influx [40], making quantitative 
measurements important for diagnosis and treatment. It should be noted that in 
these studies, pharmacological breach of the BBB was necessary for symptoms to 
occur and only achieved with intravenous administration of lipopolysaccharide or 
epinephrine, eliciting a strong cytokine response driving BBB disruption.
3.3.2 Antiribosomal P antibodies
In the late 1980s, an association was found between elevated serum titers of 
antiribosomal protein (RP) antibodies and lupus psychosis in NPSLE patients [41]. 
Lupus - New Advances and Challenges
6
Although subsequent studies continued to find an association, an international 
meta-analysis subsequently found that anti-RP antibodies had limited diagnostic 
value [20]. Still, when anti-RP antibodies from NPSLE patients were injected into 
the ventricles of mice, animals developed depressive-like symptoms as measured 
by immobility [42]. Brains of these mice also showed anti-RP antibody staining 
in the hippocampus, cingulate cortex, and the primary olfactory piriform cortex 
[42]. Interestingly, symptoms were partially reversed when a specific anti-idiotypic 
antibody to anti-RP was administered [42]. Additionally, one study found that 
human-derived anti-RP antibodies affected glutamatergic synaptic transmission 
and plasticity related to memory in the hippocampus [43]. These findings are sup-
ported by studies showing an association between depression and the presence of 
anti-RP antibodies in lupus patients [44–46].
3.3.3 Antiphospholipid antibodies
Antiphospholipid syndrome (APS) is defined by the presence of lupus anticoag-
ulant (LA) or anti-β2-glycoprotein-I (β2-GPI), which is a subset of anticardiolipin 
(aCL) antibodies. SLE patients with APS are more likely to develop infarcts, stenotic 
arterial lesions, and white matter hypertrophy compared with SLE patients without 
APS [47]. Antiphospholipid antibodies have also been associated with psychosis 
in one [48] but not another [49]. Still, a meta-analysis of autoantibodies present in 
NPSLE patients found an increased prevalence of antiphospholipid (APL) positiv-
ity in patients with cerebrovascular disease and cognitive dysfunction [50].
A similar correlation was found in animal models. Mice immunized with a 
pathogenic monoclonal aCL antibody developed hyperactive behavior in an open 
field, and examination of brain tissue revealed thrombotic capillary occlusion and 
mild inflammation [51]. To further explore aCL antibody pathogenicity, Ig from 
an APS patient was administered into the ventricles of mice and was subsequently 
found to bind to the hippocampus and cerebral cortex [52]. The level of aCL anti-
body binding correlated with poor performance on the water maze [52], suggesting 
a specific role for these autoantibodies.
Other mechanism by which APS antibodies may contribute to NPSLE manifesta-
tions are via endothelial activation and the induction of a prothrombotic state [53] 
or via directly affecting BBB permeability and thus allowing for the penetration of 
pathogenic autoantibodies such as anti-NR2 antibodies [54]. Further studies are 
needed to determine the primary mechanism of aCL antibodies and their effect on 
brain health.
3.4 Cytokines
Cytokines have been implicated in neurotoxicity. For example, when CSF from 
MRL/lpr mice was administered into the CNS of a nonautoimmune rat, it induced 
neurotoxicity and periventricular neurodegeneration [55]. Exposure to lupus CSF 
also led to reduced neuronal viability of hippocampal neurons and astrocytes in vitro, 
suggesting the presence of intrathecal neurotoxic metabolites and/or cytokines [56].
As described above, cytokines may directly act to breach the BBB [19]. For 
example, peripheral administration of lipopolysaccharide (LPS), a cytokine 
inducer, or of recombinant IL-1 and TNF-α is sufficient to decrease motor and 
social activity and reduce food and water intake, reflecting depression and anhe-
donia, respectively, in C57BL/6 mice [57, 58]. The effect was most likely mediated 
by TNFα, since mice deficient in TNF-α receptors was resistant to both depression 
and sickness behavior [59], although specific analyses separating peripheral from 
brain-specific effects were not done. Further supporting a role for cytokines is the 
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observation that increased serum levels of IL-1 correlated with blunted responsive-
ness to palatable stimulation in MRL/lpr mice [60]. Additionally, IL-6 production 
occurs early on and reduces sucrose preference, which is a behavioral alteration 
replicated by exogenous IL-6 administration [61]. IL-6 knockout mice are some-
what protected from the behavioral effects of LPS and IL-1 injection [62, 63], sug-
gesting that IL-6, as TNFα, is acting downstream of these mediators. Furthermore, 
treatment with cyclophosphamide abolished the rise in IL-6, as well as attenuated 
behavioral deficits and neuronal death in MRL/lpr mice [64, 65]. Finally, injection 
of IL-6 increased BBB permeability in rats [66].
An additional possible player is TNF-like weak inducer of apoptosis, 
TWEAK. TWEAK is a secreted ligand of the TNF family that mediates its effects 
through its receptor Fn14, and Fn14-deficient MRL/lpr mice displayed decreased 
depressive behavior and cognitive impairment as measured by decreased immobil-
ity in forced swim test and maintained preference for sweetened fluids compared to 
controls [67]. Fn14 knockout mice also showed improved BBB integrity as measured 
by albumin quotient [67], suggesting a specific effect of TWEAK on the BBB.
Separate from the typical proinflammatory cytokines (TNFα, IL-1, and IL-6), 
IFNα may play an important role in NPSLE. IFNα is an antiviral cytokine in the type 
I IFN family strongly implicated in the pathogenesis of SLE. Numerous studies have 
shown that type I IFN receptor (IFNAR) deficiency reduces disease in multiple lupus 
mouse models [68–70]. Similarly, clinical data from patients undergoing IFNα ther-
apy have shown neurotoxicity and induction of symptoms similar to those in NPSLE, 
such as cognitive impairment, seizures, and mood changes [71, 72]. In a bioassay 
containing plasmacytoid dendritic cells (the main INFα-producing cell type) and a 
source of antigen, CSF from NPSLE patients induced higher IFNα production than 
CSF from other autoimmune disease control subject [73], suggesting that specific 
antibodies and/or cytokines in CSF from SLE patients can stimulate IFNα produc-
tion, although the nature of such stimulants remains unknown. Most recently, it 
was shown that treatment of NZB/W mice with anti-IFNAR antibodies effectively 
blocked neurological symptoms and that IFNα directly affected microglia cells in 
vitro [74]. Future studies evaluating the specific lack of IFNAR expression within the 
brain will be important to determine if the effect of IFNα in NPSLE is predominantly 
peripheral or brain specific. Furthermore, studies addressing the importance of 
IFNAR expression on specific brain-associated cell subsets in vivo during disease 
development are required to develop suitable BBB-breaching therapies if needed.
In addition to a direct effect of cytokines on the BBB, it is possible that cytokines 
can target the CNS without BBB disruption. This possibility stems from studies 
showing that cytokines do not need to pass the BBB to regulate behavior [75]. The 
existence of an entity called “sickness behavior,” as characterized by lethargy, 
depression, malaise, and loss of appetite, supports the notion that immunity 
can affect behavior [57]. Sickness behavior is considered an adaptive response to 
infection that is mediated by cytokines, mainly IL-1, IL-6, and TNFα [75]. These 
cytokines have been separately implicated in the pathogenesis of psychiatric disease 
and are the same cytokines found to be elevated in MRL/lpr [76–78], NZB/W F1 
[66, 79], and human [80] studies of NPSLE as described above.
There are two ways by which cytokines can affect the brain without involving 
BBB disruption. First, cytokines may enter the brain through afferent branches 
of the vagus nerve, which contain macrophages and dendritic cells in their sheath 
[81], and secondly, phagocytic cells in brain regions surrounding the ventricles 
and the choroid plexus may themselves produce and release cytokines [82]. 
Evidence for the role of the vagus nerve includes studies that show that vagotomy 
reduces sickness behavior [83, 84] and brain IL-1 expression [85–87] in response 
to intraperitoneal LPS and IL-1. This finding may be mediated through cytokine 
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production by immune cells in the vagus perineural sheath [81]. It has also been 
found that macrophage-like cells and microglia in the brain regions surrounding 
the ventricles and the choroid plexus, which lack BBB, produce IL-1 in response to 
LPS administration [88, 89]. Thus, although the prevailing hypothesis is that BBB 
dysfunction is necessary for NPSLE manifestation, data from sickness behavior 
and depression research suggest that there may be BBB-independent cytokine-
mediated mechanisms.
In summary, cytokines contribute to NPSLE via a variety of mechanisms, 
including through the vagus nerve and periventricular brain regions without 
crossing the BBB, by directly causing BBB disruption, and/or by causing specific 
neurotoxicity.
3.5 Microglial activation
As the major immune cell type of the brain, microglia phagocytize redundant 
and unnecessary synaptic connections, thereby contributing to the structural orga-
nization of the brain and facilitating learning and memory [90]. Estrogen has been 
implicated in the pathogenesis of NPSLE via microglial activation. In female MRL/
lpr mice, global estrogen receptor (ER) α deficiency resulted in reduced numbers of 
activated hippocampal microglia and improved spatial memory, as measured by the 
Morris water maze performance, in a manner independent of serum autoantibody 
and estrogen levels [91]. However, it remains unknown if this effect was direct or 
mediated by reduced immune reactivity.
Recently, it was shown that also IFNα stimulates microglial reactivity, and 
treatment of lupus-prone mice with anti-IFNAR antibody was sufficient to reduce 
percentages of activated microglia and synapse loss, as well as prevent behav-
ioral phenotypes [74]. Moreover, increased IFNα signaling was also observed in 
postmortem hippocampal brain sections from patients [74], further supporting 
a pathogenic role for IFNα in NPSLE. Taken together, these data suggest that the 
pathogenesis of NPSLE may involve IFNα-driven and ER-mediated microglial 
activation.
4. Clinical phenotypes
4.1 Epidemiology
A prevalence as low as 12% and as high as 95% has been described for NPSLE 
manifestations. Different study designs, NPSLE symptoms studied, and population 
selection have contributed to discrepancies in reports.
The first set of standardized nomenclature was developed in 1999 by the 
American College of Rheumatology (ACR) Ad Hoc Committee on Neuropsychiatric 
Lupus Nomenclature. Case definitions were established for 19 different neuro-
psychiatric syndromes and divided into 12 central nervous system (CNS) and 7 
peripheral nervous system (PNS) manifestations, as listed in Table 1 [92]. The PNS 
manifestations are less common than CNS syndromes and are addressed elsewhere 
[93, 94]. CNS syndromes were further categorized into focal neurologic syndromes 
(cerebrovascular disease, seizures, myelopathy, aseptic meningitis, movement 
disorder, and demyelinating syndrome) and diffuse psychiatric/neuropsychological 
syndromes (cognitive dysfunction, mood and anxiety disorders, psychosis, acute 
confusional state, and headache).
As expected, the diffuse psychiatric/neuropsychological syndromes presented 
with more difficulties in diagnostic agreement due to their diverse presentations 
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and subjective nature [92]. In a subsequent cross-sectional validation study, these 
criteria were found to have a 46% specificity, thereby demonstrating inability of 
criteria to distinguish NPSLE patients from controls [95]. This low specificity was 
speculated to be partly attributed to the manifestations of NPSLE that overlap with 
other CNS conditions, as well as discrepancies in diagnosis of the diffuse neuropsy-
chological syndromes. When the validation study excluded syndromes without any 
indication of neurologic dysfunction, including headache, mild cognitive dysfunc-
tion, mild mood and anxiety disorders, and polyneuropathy without electrophysi-
ological confirmation, they were able to improve specificity to 91% [95].
To better understand the reasons for the high variability of prevalence estimates 
between different studies, Unterman et al. [96] performed a meta-analysis of 17 stud-
ies from 1999 to 2008 that applied the 1999 ACR case definitions. Using a subanalysis 
of 10 prospective studies, they found the prevalence of NP syndromes in SLE patients 
to be 56.3%, with a range from 23 to 95% [96]. In contrast, analyses of retrospective 
studies presented with a cumulative prevalence of only 17.6% [96]. A reason for this 
discrepancy may be that the syndromes that are more subjective to diagnose, such as 
headache, mood disorders, cognitive dysfunction, and anxiety, often had increased 
prevalence in prospective studies as compared to numbers obtained from retrospec-
tive studies [96]. In contrast, syndromes that may be considered more objective due 
to their measurability, such as seizures and movement disorders, showed little vari-
ability in prevalence from prospective versus retrospective studies and thus would be 
equally suitable for retrospective or prospective review.
Examination of studies at either end of the prevalence spectrum revealed 
several key characteristics influencing variability, including exclusion of subjective 
syndromes such as headache, differences in population characteristics such as age 
ACR criteria [92] Modified criteria by 
Ainiala [95]
Central nervous 
system—manifestations
Focal neurologic syndromes
Aseptic meningitis
Cerebrovascular disease
Demyelinating syndrome
Movement disorder (chorea)
Myelopathy
Seizure disorders
Diffuse psychiatric/neuropsychologica syndromes
Headache (including migraine and benign 
intracranial hypertension)
Acute confusional state
Anxiety disorder
Cognitive dysfunction
Mood disorder
Psychosis
Aseptic meningitis
Cerebrovascular disease
Demyelinating syndrome
Movement disorder 
(chorea)
Myelopathy
Seizure disorders
Acute confusional state
Cognitive dysfunction 
(moderate or severe)
Severe depression
Psychosis
Peripheral nervous 
system—manifestations
Acute inflammatory demyelinating 
polyradiculoneuropathy (Guillain-Barre´ 
syndrome)
Autonomic disorder
Mononeuropathy, single/multiplex
Myasthenia gravis
Neuropathy, cranial
Plexopathy
Polyneuropathy
Acute inflammatory 
demyelinating 
polyradiculoneuropathy
Autonomic disorder
Mononeuropathy, single/
multiplex
Myasthenia gravis
Neuropathy, cranial
Plexopathy
Polyneuropathy (with 
ENMG confirmation)
Table 1. 
ACR criteria for NPSLE syndromes.
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and race, and the level of detail in diagnosis, including the use of a comprehensive 
neurocognitive battery [96]. It should be noted that of the 19 syndromes defined 
by the ACR, none is specific to NPSLE, and thus when assessing prevalence and 
impact, comparison to control populations and attribution to SLE versus other 
diseases are important.
NPSLE diagnosis is still currently a process of exclusion, which requires a 
detailed history and comprehensive evaluation to rule out other causes of symp-
toms, such as primary neurological or psychiatric disease [97]. Laboratory studies 
are important to support a NPSLE diagnosis, in particular markers of inflammation 
such as erythrocyte sedimentation rate and complement levels [97]. Of the serum 
autoantibodies, perhaps the most consistently present are the serum aPL, with an 
estimated prevalence of 45% in NPSLE patients [98, 99], although it should be 
noted that presence of these autoantibodies does not preclude the possibility of 
concurrent SLE and primary neuropsychological disease.
4.2 Cerebrovascular disease
Cerebrovascular disease stemming from SLE is thought to be at least partially 
caused by antiphospholipid (aPL) antibodies, leading to thrombosis in cerebral 
vasculature [1]. Identified risk factors for cerebrovascular disease include chronic 
and high disease activity, high cumulative corticosteroid dose, persistently elevated 
titers of aPL antibodies, heart valve disease, and systemic hypertension [100, 101]. 
An additional contributor to cerebrovascular disease is the observation of prema-
ture atherosclerosis in the vasculature of SLE patients, which occurs independently 
of traditional cardiovascular risk factors [102]. Data in support of this include 
increased prevalence of carotid plaque in SLE patients compared with age- and 
sex-matched controls even after adjustment for traditional risk factors [103]. A 
recent study shows that the relative risk of subclinical atherosclerosis in SLE was 
comparable to that found in diabetes mellitus, a well-known and major risk factor 
for cerebrovascular disease [104]. Cerebrovascular disease can lead to events such 
as stroke, which can then lead to other NPSLE syndromes such as cognitive dys-
function [105].
4.3 Seizures
Seizures often occur early in NPSLE disease progression and are positively cor-
related with African race/ethnicity, lower educational status, and cumulative organ 
damage [106]. The correlation with race and education may be a reflection of socio-
economic status [107], which is a predictor of both functional status and mortality 
[108] and may influence access and adherence to treatment [106]. In prospective 
cohort studies, the most common seizure type was primary generalized; however, 
some patients also had partial episodes [109, 110]. Cerebral atrophy and cerebrospi-
nal fluid (CSF) pleocytosis are common findings in NPSLE, perhaps suggesting that 
there may be a lupus-related encephalopathic process seizure pathogenesis [93]. 
Independently of other symptoms, seizure occurrence can be an indicator of the 
level of disease activity [109, 111].
Seizures may occur many years before SLE diagnosis, potentially leading to 
erroneous diagnoses of epilepsy [109]. This misdiagnosis may be prevented by 
obtaining antinuclear antibody (ANA) and anti-double-stranded DNA (anti-
dsDNA) levels, as these are commonly elevated in patients with seizures attribut-
able to SLE [112] and would further support SLE as the etiology. In one larger 
prospective study, most seizures resolved without a negative impact on quality of 
life and did not require long-term antiseizure medication, although a smaller study 
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found a need for long-term continuous treatment with antiepileptics [113]. This 
discrepancy may be due to the latter study being retrospective, allowing for longer 
follow-up time. Seizure prevalence varies, as is the case with estimates of all NPSLE 
symptoms; however, most larger studies found a cumulative frequency of 5–10% of 
SLE patients [106, 109, 113].
It remains unclear if aPL antibodies are associated with seizure occurrence, as 
one study showed a positive correlation with seizure recurrence [114], while others 
did not [106, 111, 113]. Because antibody titers were not always measured close 
to seizure event time points, further studies are needed to better understand how 
antibodies may change with disease activity and therefore influence seizure occur-
rence. There is evidence, however, that antibodies may directly induce seizures by 
increasing neuronal excitability through inhibition of GABA receptors [115] and 
permeabilization and depolarization of brain synaptoneurosomes [116]; however, 
it is also possible that aPL antibodies lead to strokes, which predispose patients to 
seizures [111, 117]. Thus, aPL antibodies and strokes are confounding factors for 
seizure etiology [114].
Finally, consistent evidence supports a protective effect of antimalarials for 
seizure occurrence as well as overall survival [106, 118]. Evidence for a mechanism 
includes studies that show antimalarials interfering with interferon-α production 
and immune complex formation by preventing incorporation of RNA and DNA 
fragments into Toll-like receptors 7 and 9, respectively [119, 120]. Authors have 
also found lipid-lowering effects of antimalarials via interference with lipoprotein 
lipase activity [121–123]. Lastly, antithrombotic properties of antimalarials have 
been demonstrated in both mice [124] and patients [125, 126]. Thus, protection 
from seizures with the use of antimalarial agents may be related to the prevention of 
thrombosis.
4.4 Myelopathy and demyelination syndrome
Myelopathy is a general term used to describe any disorder of the spinal cord 
leading to paraparesis and/or sensory impairment, which can arise from a number 
of etiologies, such as ischemia, compression, metabolic, and inflammatory causes 
[127]. Myelitis technically refers to when a spinal lesion is secondary to inflamma-
tion; however, the two are often used interchangeably in the literature [127]. In 
the 1999 ACR criteria (see Table 1), myelopathy and demyelination syndrome are 
considered separate entities, with myelopathy referring to any rapidly involving 
spinal cord lesion, whereas demyelination syndrome encompassed demyelinating 
lesions anywhere in the CNS, which includes transverse myelopathy [92]. Due to the 
considerable overlap in these two syndromes, they will be considered together here.
Myelopathy in NPSLE usually refers to transverse myelitis (TM), which is an 
early, rapidly evolving but very rare manifestation (~1%) [96, 97]. The mechanism 
can be ischemic or inflammatory in nature, and symptoms typically manifest 
as flaccidity and hyporeflexia or spasticity and hyperreflexia [128]. Transverse 
myelopathy has been identified as the first manifestation of SLE [129] and has 
been associated with aPL positivity [130], suggesting aPL-induced thrombosis as a 
potential mechanism [131]. The evidence, however, has not been consistent  
[132, 133], and the presence of thrombosis does not explain involvement of differ-
ent levels of the spinal cord [134]. Some have suggested an aPL-induced vasculitis 
of spinal vessels [135] and loss of perfusion secondary to spinal cord swelling [128] 
as alternative mechanisms.
Demyelinating syndrome in lupus has been termed lupus sclerosis to indicate 
the clinical similarities with MS, such as optic neuritis, brainstem and cerebellar 
syndromes, spastic paraplegia, and other transient neurological deficits [93].  
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The term “clinically isolated syndrome” was originally developed to describe the 
first demyelinating episode suggestive of MS [136], but it could also be the first 
demyelinating episode of NPSLE [134]. Pathological studies confirmed that lupus 
sclerosis was indeed distinct from MS, with no evidence of primary demyelination 
[137]. Misdiagnosis can have disastrous consequences, as treatments for MS, 
especially interferon-based therapies, can exacerbate SLE [138]. Certain clinical 
findings, such as the concomitant presence of renal involvement, rash, arthritis, 
myalgia, PNS involvement, and meningismus, might indicate SLE as the underlying 
diagnosis [134]. Moreover, the presence of cerebrovascular disease or thrombotic 
events is the clue for concomitant or primary APS [139]. In fact, one study found 
that 8% of patients with aPL positivity had a previous diagnosis of MS or MS-like 
symptoms [140], suggesting that aPL screening should be conducted in patients 
presenting with MS-like symptoms, particularly since it is noninvasive and inexpen-
sive [134, 141].  
Additionally, high ESR, ANA, and lack of oligoclonal immunoglobulin bands in the 
CSF would support NPSLE etiology. Whereas type I IFN activity is elevated in SLE 
and implicated in its pathogenesis, type I IFN activity is low in MS [142] and IFNβ 
is actually used as a treatment for MS [143]. This difference suggests that measur-
ing serum type I IFN activity may be a useful way to distinguish patients who have 
demyelinating syndrome from SLE versus MS [142].
Optic neuritis in NPSLE is characterized by pain with ocular movements and 
visual impairment [134], and similarly, TM can be the first presentation of SLE and 
has been associated with aPL [144]. The combination of TM and optic neuritis is 
termed neuromyelitis optica (NMO). In a small cohort of SLE patients with white 
matter myelitis, NMO was found in roughly half of the patient population [128]. 
Interestingly, NMO is also associated with aPL positivity in addition to the presence 
of antiaquaporin autoantibodies [128, 145]. Antiaquaporin antibodies are specific 
to NMO and present in the sera of SLE patients years before the first NMO attack 
[146]. Additionally, serum IFNα activity was found to be high in NMO patients, 
similarly to patients with SLE [142], suggesting that NMO and SLE may share at 
least some similarities in pathophysiology.
NMO was only recently recognized to be an independent entity rather than a 
subset of MS [145, 147]. Additionally, because TM, optic neuritis, and NMO all have 
associations with aPL positivity, studies have suggested an intersection between 
SLE, MS, and APS [138, 141, 148]. Given that the literature on myelopathy in 
SLE still consists of mostly case studies [129, 130, 149–152], larger cohort studies 
are needed to better characterize these patients and distinguish pathogenesis of 
myelopathy from SLE versus MS. Additionally, a considerable amount of knowledge 
has been gained in the past two decades about various forms of myelopathy, and it is 
reasonable to consider reorganizing these syndromes in a revision of the 1999 ACR 
classification system [153].
4.5 Aseptic meningitis
Aseptic meningitis is a rare feature of NPSLE, but when it does present, it 
is usually earlier in the disease course and may signal the advent of other CNS 
complications such as transverse myelitis and strokes [93]. Diagnosis usually 
involves leukocytosis evident on cerebrospinal fluid analysis. Notably, nonsteroidal 
antiinflammatory drugs (NSAIDs) can cause aseptic meningitis [93]. Anywhere 
from 25 to 84% of lupus patients are treated with NSAIDs for symptoms such as 
synovitis, serositis, fever, soft tissue pain, and headache [154], making it difficult to 
determine the initiating factor. Regardless, many patients who experience drug-
induced aseptic meningitis have SLE, suggesting that there may be some inherent 
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predisposition, although the mechanism is unknown [155]. In summary, adverse 
medication events may complicate the diagnosis of primary versus treatment-
induced aseptic meningitis. Drug discontinuation is currently the only method to 
distinguish between these, as complete recovery can be observed after several days 
of drug discontinuation in drug-induced aseptic meningitis [155].
4.6 Movement disorders
Movement disorders in SLE are infrequent in adult NPSLE patients (<2%), 
although more frequently observed in juvenile SLE. When it occurs, it is often asso-
ciated with an acute flare and predominantly in women under the age of 30 years 
[93]. Manifestations include rigidity, tremors, masked facies, chorea, and akinesia, 
although symptoms are often transient in nature [93, 97].
4.7 Cognitive dysfunction
In 1999, the ACR committee proposed a standard 1-hour battery of neuropsy-
chological tests to assess cognitive function [92], which has since been tested and 
established for reliability and validity [156]. The definition of dysfunction included 
significant deficits in simple or complex attention, reasoning, executive skills, 
memory, visual-spatial processing, language, or psychomotor speed [92]. Studies 
have used different types and lengths of neuropsychological testing, thus contribut-
ing to a wide range of prevalence anywhere from 0 to 80% [156]. When the 1-hour 
battery as proposed by the ACR is used, the prevalence of cognitive dysfunction has 
a narrower range of between 23 and 60% [156].
Cardiovascular risk factors have been found to be related to the severity of 
cognitive dysfunction in SLE, in particular hypertension, which is also a risk factor 
for cognitive impairment in the general population [105]. In addition, hyperten-
sion itself has been associated with brain atrophy and cognitive dysfunction [157] 
and thus may contribute to the risk of cognitive dysfunction independently of 
SLE. Because cognitive impairment is also a common sequela of stroke [158], the 
association with aPL positivity may in fact be due to an occlusive vasculopathy [49]. 
Thus, screening for cardiovascular risk factors in SLE patients presenting with aPL 
positivity is important, as the risk for stroke may be significantly increased above 
baseline in these patients. Furthermore, this finding emphasizes that cognitive dys-
function is often sequelae of cerebrovascular events and may be prevented in some 
cases by addressing hypercoagulability and cardiovascular risk in SLE patients.
4.8 Mood changes
Mood changes in NPSLE encompass major depressive-like episodes, mood 
disorders with depressive, manic or mixed features, anxiety, panic disorders, and 
compulsion, with depression being the most common [97]. Not surprisingly, SLE 
disease activity is correlated with the presence and severity of major depression 
[159]. This connection may be a result of a multitude of mechanisms, including an 
independent association between mood and cardiovascular risk factors [100], as 
well as the psychological burden of having SLE in the first place, including illness 
stigma [160]. As discussed previously, elevated cytokine levels may also contribute 
to depression and anhedonia in NPSLE patients [75].
Similarly to psychosis (see below), it is important to determine if mood dis-
orders are a result of primary psychiatric disease or secondary to corticosteroid 
therapy, as studies have shown a correlation between corticosteroid usage and 
several mood disorders [161–164]. Mania seems to be more commonly caused by 
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acute corticosteroid therapy [161, 163], whereas long-term therapy is more likely to 
lead to depressive symptoms [164]. Psychiatric disorders typically occur within the 
first 6 weeks of corticosteroid treatment and are dose dependent [161]. Up to 90% 
of patients recover completely with discontinuation or a reduction in dosage [161]. 
Additionally, when mood disorders are the initial presentation of NPSLE, cortico-
steroids are not typically used. Rather, patients usually receive antidepressant and 
antipsychotic medications, which are effective in treating mood disorders second-
ary to NPSLE [162]. Thus, corticosteroid-induced mood changes are a confounding 
factor only when mood changes develop after NPSLE diagnosis and subsequent 
steroid therapy, and withdrawal of steroids and use of antidepressant/antipsychotic 
medications would be warranted at that time. Factors that would suggest an SLE 
etiology rather than an iatrogenic one include the presence of a chronological 
association, imaging and EEG abnormalities, non-CNS manifestations of SLE, and 
serious disturbances in memory and concentration [162].
4.9 Lupus psychosis
Psychosis is a disturbance in perception of reality usually characterized by 
delusions and/or hallucinations, in the absence of delirium, and causing significant 
distress or functional impairment [165]. Psychosis is a relatively rare event in SLE 
that, similarly to seizures, occurs early and transiently in disease course, if at all 
[144, 166]. The reported prevalence varies from 0 to 11% [167–169].
The ACR Committee adopted terminology from the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV) [170], and lupus psychosis 
falls under “psychosis due to a general medical condition” (DSM-IV 293.81/82), 
which excludes schizophrenia and brief psychotic disorder, as well as bipolar 
disorder [170]. Thus, NPSLE patients with psychosis secondary to schizophrenia, 
brief psychotic disorder, or bipolar disorder, although few, would not be captured 
under the category of lupus psychosis per strict ACR case definitions [166].
In a retrospective study of 11 patients with primary lupus psychosis and a mean 
follow-up of 13 years, all had good response to intensive immunosuppressive treat-
ment at the time of diagnosis and 70% achieved complete remission, suggesting a 
favorable long-term prognosis [166]. When diagnosing patients, it is important to 
distinguish lupus psychosis from iatrogenic steroid psychosis, for which hypoalbu-
minemia may be a risk factor [171]. Steroid psychosis is typically dose-dependent, 
occurs within 8 weeks of initiation, and usually resolves completely with dose 
reduction [162]. It should be noted that SLE itself is linked to a higher risk of steroid 
psychosis, possibly related to BBB damage, another risk factor for steroid psychosis. 
Therefore, it is important to identify new clinical readouts that are more suggestive 
of NPSLE, such as non-CNS manifestations, severe deficits in memory and concen-
tration, or focal neurologic deficits [162]. Moreover, there are a number of agents 
that can be used for prophylaxis of steroid-induced neuropsychiatric disorders; 
thus, if steroid therapy is unavoidable, concurrent administration with valproate 
and lithium should be considered.
4.10 Acute confusional state
Acute confusional state is synonymous with encephalopathy and is character-
ized by impaired consciousness or level of arousal, which can progress to coma 
[172]. It is rarer than the other CNS syndromes, with a reported prevalence of 4–7% 
of SLE patients [173]. The etiology of acute confusional state in SLE remains to be 
determined, as SLE-nonspecific events such as infections and metabolic distur-
bances can also cause this syndrome [174].
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4.11 Headache
In a meta-analysis of 35 studies of headache in NPSLE, the prevalence of 
all headache types, including migraine, was not different from controls, and 
insufficient evidence was found for the concept of “lupus headache” [175, 176]. 
Additionally, no specific mechanism for headache in SLE patients exists, and there is 
no link between headache and disease activity or cumulative organ damage  
[175, 177]. Pooled prevalence in this meta-analysis was 50.2%, in contrast to a much 
lower 12.2% in a more recent meta-analysis [96]. The estimate is closer to 30% if 
only prospective and elicited studies are included [96], suggesting that there is 
either underreporting in retrospective reviews or perhaps a component of recall 
bias in prospective studies. Additionally, it has been observed that headache preva-
lence can vary considerably with cultural differences, as Asian populations tend to 
report headache less frequently [178].
A recent prospective study of an international cohort found no link between 
headache and specific autoantibodies at time of study enrollment [177]. Although 
headaches negatively impacted quality of life, most headaches resolved indepen-
dently of lupus-specific therapies [177], further supporting the lack of evidence for 
“lupus headache.” There is inconsistency in diagnosing headache associated with 
SLE, even by physicians who specialize in SLE, and it remains unclear whether 
headache in SLE patients exists as an entity independent of other NPSLE events, 
such as meningitis, seizure, and cerebrovascular disease, and whether it warrants 
measurement as included in ACR criteria [175, 177].
The International Headache Society (IHS) has established criteria for the clas-
sification of all headaches, and in a 2008 study, they were found to be more exhaus-
tive than current ACR criteria and include categories such as chronic headache 
disorders, which were not included in the ACR criteria [176]. Thus, some headache 
disorders may not be classified [176]. Discrepancies in headache classification may 
also explain prevalence variance. Additionally, cluster headaches are included in the 
criteria but evidence for its existence in NPSLE is sparse. This weakness suggests 
that ACR criteria may be in need of revision, especially given that IHS criteria is 
already used as the basis for clinical trials of headache treatments.
4.12 Summary
In conclusion, the clinical syndromes of NPSLE are varied and each presents 
with challenges in diagnosis and classification. The ACR criteria are in need of an 
update to offer more specificity, as pathogenetic mechanisms cannot be elucidated 
if there is no consensus about which patients have the syndrome. Because none of 
the syndromes discussed above are unique to NPSLE, there are often already pre-
existing classification criteria, such as those for headaches and psychosis. As such, 
it is important in future studies to adhere to more stringent and consistent criteria 
rather than using inconsistent classification or evaluation methods. This approach 
would likely also limit the high variability in prevalence estimates of all NPSLE syn-
dromes, notwithstanding the already subjective nature of many of these syndromes 
as well as differences in population characteristics. Many of these syndromes, 
such as seizures, myelopathy, and psychosis, present early on and can be the initial 
manifestation of NPSLE. Thus, as is the case with any disease, successful diagnosis 
of NPSLE starts with its inclusion on the list of differentials, although it remains 
a diagnosis of exclusion due to the lack of consistent biomarkers. A recent review 
detailed a diagnostic algorithm incorporating ACR case definitions and results from 
other studies suggesting modifications [94], and use of this may likely improve 
diagnostic accuracy and precision of prevalence estimates for future studies.
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5. Evaluation and diagnosis
5.1 Imaging
A variety of imaging modalities are available for use in patient evaluation, 
including both anatomical imaging, such as CT, MRI, and magnetization transfer 
imaging, as well as functional imaging, such as functional MRI, PET, and SPECT 
imaging [97]. For a review of the most prevalent findings in NPSLE for each 
modality, see the review by Jeltsch-David and Muller [97]. As expected, the focal 
neurologic syndromes, namely seizures, cerebrovascular disease, myelopathy, and 
demyelinating syndrome, have the most identifiable imaging manifestations. MRI 
is perhaps the most commonly used technique due to its availability and popularity 
as an anatomical imaging modality, despite its poor sensitivity and specificity for 
NPSLE [97]. Additionally, MRI is often used in the workup of primary neurological 
diseases and is necessary to exclude these in the etiology of symptoms. For example, 
MRI can help to exclude infection and malignancy [131], and since NPSLE is a diag-
nosis of exclusion, MRI is a necessary part of the evaluation. Additionally, specific 
MR sequences with fluid attenuated inversion recovery and diffusion weighted 
imaging are recommended to improve sensitivity and specificity [93].
5.2 Biomarkers
Patient evaluation consists of first collecting a detailed medical history and 
ensuring exclusion of more common etiologies of NPSLE symptoms prior to 
chasing a diagnosis of neurolupus [97]. Only then, it is worthwhile to pursue 
broad laboratory investigation, such as CSF analysis, complement levels, erythro-
cyte sedimentation rate, as well as autoantibody panels. Identification of reliable 
biomarkers remains elusive, hence the continued need for pathogenetic inquiry 
[97]. Mechanisms are complex, and due to the diversity of presentations, no 
single pathway has been identified as a sole marker of disease. However, some 
commonalities include BBB dysfunction, vascular occlusion, neuroendocrine-
immune imbalance, tissue damage mediated by autoantibodies and proinflamma-
tory cytokines, and direct neuronal cell death [97]. Additionally, it is important 
to consider the heterogeneity of the studied population and assays used to assess 
antibody levels [179].
Antibodies to consider measuring include those targeting phospholipids, 
ribosomal P peptides, glial fibrillary acidic protein (GFAP), NMDA receptor, 
microtubule-associated protein 2 (MAP-2), and matrix metalloproteinase 9  
(MMP-9). As outlined above, many of these have also been identified in animal 
models of NPSLE, further supporting potential causative and/or diagnostic 
relationships. Details on the specificity and association of each of these antibody 
specificities with each NPSLE syndrome were recently summarized [97]. In a recent 
meta-analysis of 41 studies of serum and CSF autoantibodies in NPSLE, signifi-
cantly more NPSLE patients demonstrated positivity for serum aCL Abs, LA Abs, 
anti-RP Abs, antineuronal Abs, and CSF antineuronal antibodies as compared to 
SLE patients [50]. Thus, they suggest that measurement of these antibodies may 
help to identify patients at the risk of developing NPSLE.
It is important to note that multiple measurements of antibodies are needed 
for the most complete assessment, as antibody levels have been shown to fluctuate 
with time and disease activity (flares) [179]. Specific testing recommended for each 
syndrome is detailed elsewhere [131]. Measurement of aPL antibodies is warranted 
particularly if patients present with cerebrovascular disease, seizures, myelopa-
thy, or cognitive dysfunction, as aPL-induced thrombosis is implicated in the 
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pathogenesis of these conditions. Positivity for aPL also influences management, as 
discussed further below.
Importantly, none of these antibodies have an adequately consistent association 
to qualify as a reliable biomarker, with even the most studied antibodies peaking 
at around 50% for prevalence in patients with NPSLE [97]. For example, antiribo-
somal P antibodies generated a great deal of interest, due to its early discovery in 
patients with lupus psychosis [41]. However, although early studies found diagnos-
tic value, more recent studies shed doubt on its accuracy for NPSLE diagnosis [20]. 
A handful of cytokines, however, do show promise as being consistently elevated, 
among which is the aforementioned IFNα [73, 97]. Thus, more research is needed 
to determine if IFNα or other cytokines, such as IL-6, IL-8, and IL-10, would be 
suitable biomarkers or markers of disease activity.
6. Management
Due to the dearth of controlled trials for NPSLE therapy, current clinical 
practice is still defined by either addressing inflammation with immunosuppres-
sive medication or ischemia and thrombotic events with anticoagulants [180]. 
Immunosuppression, which is still currently the mainstay of treatment for NPSLE, 
consists of corticosteroids alone or in combination with a second immunosuppres-
sive agent [131]. Options for additional immunosuppression include cyclophospha-
mide, azathioprine, mycophenolate mofetil, methotrexate, cyclosporine, rituximab, 
intravenous immunoglobulins, therapeutic plasma exchange, and hematopoietic 
stem cell transplant as a last resort [131]. Because corticosteroids have the most 
immediate antiinflammatory effect, they are often used in treatment of SLE disease 
flares, although dosing is still often empirical [181]. In addition to the previously 
discussed side effects of mood disturbances and psychosis, glucocorticoids can 
also cause hypertension, dyslipidemia, and increase the already elevated risk for 
cerebrovascular events in SLE [182]. Keeping doses <7.5 mg/day as well as the use of 
methylprednisolone pulses rather than long-term steroid therapy may help to miti-
gate the long-term adverse effects [183]. Thus, steroid therapy for NPSLE should be 
administered judiciously, and it may be prudent to use the minimum effective dose 
and titrate up as needed, reserving the higher doses for the acute setting.
Of the other immunosuppressive agents, cyclophosphamide was the only one 
tested in a randomized controlled clinical trial in acute, severe NPSLE, which 
found that treatment response was higher in the cyclophosphamide group versus 
the methylprednisolone group [184]. However, a subsequent Cochrane review 
categorized this study as low quality evidence due to its small size and high risk of 
allocation concealment, blinding, and selective reporting [185], thus highlighting 
the need for more high-quality randomized controlled trials evaluating the different 
immunosuppressive agents. Of the remaining options, azathioprine is most often 
used clinically as maintenance therapy following cyclophosphamide induction 
due to its milder side effect profile, and rituximab is used as a second-line therapy 
for severe, refractory NPSLE, although none of these agents have sufficient high-
quality evidence to support their use [131].
Symptomatic therapy, which does not address the underlying pathology of 
NPSLE, is often the first treatment for SLE patients presenting with NP symptoms 
due to a lack of recognition of NPSLE [131]. Examples include antidepressive 
and antipsychotic agents for mood disturbances and psychosis, antiepileptics for 
seizures, dopamine agonists for movement disorders, and NSAIDs for headache 
[131]. These agents can be sufficient for symptomatic control in those with mild 
NPSLE disease. In those experiencing cognitive dysfunction or mood disturbances 
Lupus - New Advances and Challenges
18
secondary to the psychological burden of disease, psychoeducational group inter-
ventions may be beneficial [186, 187].
Primary prevention strategies, defined as preventing the onset on NPSLE, 
have been suggested with the use of hydroxychloroquine [144, 188], which is 
advantageous since hydroxychloroquine is a widely used and safe therapy for 
SLE [131]. As discussed previously, antimalarials are associated with less damage 
accrual [189] and have been shown to reduce mortality [118, 190], reduce car-
diovascular disease and thrombotic risk [122, 123], and protect against seizures 
[106]. Statins may affect the regulation of inflammatory processes leading to ath-
erosclerosis [191] and thus would be a reasonable agent to consider in the primary 
prevention of cerebrovascular events in NPSLE. However, a 2-year trial of statin 
therapy showed no benefit in primary or secondary atherosclerosis outcomes in 
SLE patients [192]. Accordingly, statins should be started in NPSLE patients with 
hyperlipidemia who meet criteria based on current cardiovascular disease guide-
lines [131]. Lastly, antiplatelet agents and anticoagulants are crucial for primary 
and secondary prevention of thrombotic complications in NPSLE patients [131]. 
Recommendations from a task force published in 2011 state that SLE patients 
with medium-high titers of aPL-antibodies should receive primary thrombo-
prophylaxis with hydroxychloroquine and low-dose aspirin [193]. In a more 
recent randomized controlled trial of 166 SLE patients with aPL, no difference in 
thrombosis rate was found between those that received low-dose aspirin versus 
low-dose aspirin plus low-intensity warfarin [194]. Those with aPL-antibodies 
should also receive low-molecular-weight heparin for prophylaxis during high-
risk situations, such as surgery or prolonged immobilization [193]. Low-dose 
aspirin is still recommended in patients with aPL even if they do not have SLE 
[193]. Patients diagnosed with APS following a thrombotic event should receive 
heparin followed by long-term anticoagulation with warfarin [193]. It is worth 
noting that the newer direct oral anticoagulants (DOACs), such as thrombin 
inhibitor dabigatran and antifactor Xa inhibitors rivaroxaban and apixaban, may 
be advantageous due to their fixed dosing and more predictable anticoagulant 
effects as compared to warfarin. Currently, insufficient evidence exists to recom-
mend their use in APS, SLE and NPSLE, although ongoing trials are investigating 
their efficacy in APS specifically [195].
6.1 Potential future therapies
In addition to the lack of evidence for the use of broad immunosuppression in 
NPSLE, many of the drugs described above have an array of adverse and poten-
tially debilitating side effects [131]. This emphasizes the need for more targeted 
therapies that may have greater efficacy in additional to minimizing the side effect 
profile. Some future candidates include factors implicated in BBB dysfunction, 
such as TWEAK, a pro-inflammatory cytokine in the TNF superfamily, as well as 
eculizumab, a humanized monoclonal antibody that blocks terminal complement 
generation, which again interferes with BBB integrity [131].
Of the potential future targets, perhaps the most promising is IFNα. Treatment 
with anti-IFNα antibodies has been shown to reduce SLE disease activity [196], and 
as previously discussed, IFNα has been consistently implicated in mouse models 
[68, 74, 197] and patients [73, 198] with NPSLE. More recently, anifrolumab, a 
type I IFN-receptor antagonist, was explored as a treatment option for moderate to 
severe SLE [199]. Unfortunately, patients with CNS syndromes were excluded in 
this study. Given the evidence for a pathogenic role of IFNα in mouse models of SLE 
and the identification of elevated IFNα levels in NPSLE patients, it will be impor-
tant to study the response to anifrolumab therapy in NPSLE patients [74].
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7. Conclusion
In summary, NPSLE is a debilitating disease that affects a number of SLE 
patients. Due to diverse presentations and overlap with other diseases, it is a 
particularly challenging entity to characterize and study. Here, we have reviewed 
the basic science, including commonly used mouse models, the involvement of the 
BBB, autoantibodies, cytokines, and microglial activation. We have also covered the 
various clinical phenotypes, emphasizing the wide range in reported prevalence, 
lack of suitable biomarkers, and steps in evaluation and management. The informa-
tion presented herein calls for further research into the basic mechanisms driving 
NPSLE to ultimately improve quality of life for patients with this disease.
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